Reacción a "EMA recommends not to approve lecanemab against Alzheimer's disease"

Today the EMA has taken the decision not to register Leqembi™ in the EU. This decision brings with it two major concerns, both for the clinical, medical and care community, as well as for the research community. Patients in Europe will be discriminated against, they will not have the same options and opportunities as patients in other countries. And in terms of research and investment in research, Europe will also be in second place.

We will pass the desert again. We will be in the middle of a drought again. And this will affect the quality of patients and their families, the research capacity of Spanish researchers and clinicians and in itself will impoverish our entire healthcare system by not having the opportunity to collect data from the real world (real world evidence) to understand, to improve and to change the frequency-doses of new products that may appear and to invest. To invest especially in the research of treatments much more effective than this one, undoubtedly, for the benefit of our citizens.

This is the position of the Ace Foundation, the clinical department and the research department, and we regret this decision of the EMA.